|

JSB462 Clinical Trials

1 actively recruiting trial across 1 location

▼ -1 trial since June 2026

Also known as: luxdegalutamide

Pipeline

Phase 2: 1

Top Sponsors

  • Novartis Pharmaceuticals1

Indications

  • Metastatic Hormone-sensitive Prostate Cancer1
  • Cancer1

La Jolla, California1 trial

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

University of California San Diego - Moores Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.